StreetAlpha
13F holdings · Q3 2026

Lynx1 Capital Management

Dorado, PR · files as Lynx1 Capital Management LP
Know the moment Lynx1 Capital Management filesYou follow Lynx1 Capital Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1910456

Lynx1 Capital Management reported 31 stocks worth $646M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are GHRS (48.2%), CGEM (21.3%) and STOK (15.7%). Compared with Q2 2026, the fund opened new positions in KZIA, SRZN and YARW, added to CCCC, DTIL and KRRO, trimmed STOK and AGIO and sold out of CGON.

Latest filing: what Lynx1 Capital Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
6 new6 added2 trimmed2 sold outBought about $19.1M · sold about $105M
New 6
See all 6 →
Added 6
See all 6 →
Trimmed 2
Sold out 2
  • CGON$2.2M
  • Vyne Therapeutics $1.1M

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$646M−25.4% vs last quarter
Stocks held316 new · 2 sold out
Top 5 weight91.7%very concentrated
Turnover19%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
GHRS
GH Research PLC
$311M48.2%13.3MNo change8 of 8
2
CGEM
Cullinan Therapeutics Inc
$138M21.3%9MNo change8 of 8
3
STOK
Stoke Therapeutics Inc
$101M15.7%3.9M−142K (−4%)8 of 8
4
CCCC
C4 Therapeutics Inc
$25.1M3.9%7.5M+204K (+3%)8 of 8
5
DTIL
Precision Biosciences Inc
$17.3M2.7%2.8M+1.8M (+190%)8 of 8
6
AGIO
Agios Pharmaceuticals Inc
$15.7M2.4%473K−2.9M (−86%)4 of 8
7
KRRO
Korro Bio Inc Com
$15.3M2.4%1.5M+6,684 (+0%)4 of 8
8
NEUP
Neuphoria Therapeutics Inc
$3.1M0.5%875KNo change7 of 8
9
PASG
Passage Bio Inc
$3M0.5%674KNo change5 of 8
10
PRQR
Proqr Thrapeutics N V
$2.6M0.4%1.6M+1M (+200%)4 of 8
🔒 21 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
CGON
CG Oncology Inc
$2.2M31K
VYNE THERAPEUTICS INC C
$1.1M1.6M

Reported value

last 8 quarters
$267MQ4 '24
$279MQ1 '25
$346MQ2 '25
$491MQ3 '25
$494MQ4 '25
$633MQ1 '26
$866MQ2 '26
$646MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Lynx1 Capital Management 13F FAQ

What does Lynx1 Capital Management own?

Lynx1 Capital Management reported 31 stocks worth $646M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are GHRS (48.2%), CGEM (21.3%) and STOK (15.7%). The table above lists every position in the filing (the top 10 without an account).

What did Lynx1 Capital Management buy and sell in Q3 2026?

Compared with Q2 2026: 6 new positions, 6 added to, 2 trimmed and 2 sold out. New positions include KZIA, SRZN and YARW. It sold all of CGON.

When will Lynx1 Capital Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Lynx1 Capital Management's portfolio worth?

The Q3 2026 filing reports $646M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.